Prolium
Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager, for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The New York-based company in-licensed the asset from KeyMed and InnoCare.
- Company typePrivate
- Founded2026
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Prolium does
Prolium Bioscience is a privately held, clinical-stage biotechnology company headquartered in New York City that develops therapies for severe autoimmune diseases. The company's stated focus is on patients with treatment-refractory systemic sclerosis, systemic lupus erythematosus, and lupus nephritis—an underserved population with limited therapeutic options. Prolium operates as a single-asset biotech built around a bispecific antibody platform.
The company's sole pipeline candidate is PRO-203, a CD20xCD3 bispecific T-cell engager designed to deplete pathogenic B-cells by simultaneously engaging CD20 on B-cells and CD3 on T-cells for targeted cytolysis. PRO-203 was in-licensed from KeyMed Biosciences and InnoCare Pharma, giving Prolium global rights in all non-oncology indications and ex-Asia rights in oncology. Prior Phase 1/2 data in relapsed/refractory non-Hodgkin lymphoma showed a 59% complete response rate and 82% overall response rate at therapeutic doses, which the company cites as supporting a potential best-in-class profile in autoimmune applications. As of mid-2026, Prolium had dosed healthy volunteers in a single ascending dose study, treated five lupus nephritis patients in an investigator-initiated study, and dosed the first patient in a multinational Phase 1/2 study in systemic sclerosis.
Prolium is pre-revenue and has no commercial products. Its revenue model is pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacies, hospital systems, and direct physician administration. The company raised a $50 million Series A in March 2026 led by founding investor RTW Investments to fund clinical development and R&D expansion. Leadership consists of founder and CEO Scott Requadt, CMO Salim Mujais, VP of Clinical Development Niki Bili, and VP of CMC & Manufacturing Bob Huang, supported by a small (1-10 employee) team.
Prolium firmographics
Firmographics- Name
- Prolium
- Legal name
- Prolium Bioscience
- Website
- https://proliumbio.com.
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager, for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The New York-based company in-licensed the asset from KeyMed and InnoCare.
- Ownership category
- akta.pro rank
Prolium industry classification
Industry- Product category
- Biopharmaceuticals / Autoimmune Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where Prolium is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prolium business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical stage biotechnology company developing PRO-203 for severe autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Prolium product offering
Product offeringCore offering
Prolium Bioscience is developing PRO-203, a bispecific CD20xCD3 T-cell engager antibody in-licensed from KeyMed Biosciences and InnoCare Pharma, for the treatment of severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. The company is currently running a single ascending dose study in healthy volunteers and plans a multinational Phase 1/2 study in systemic sclerosis.
Product overview
Prolium Bioscience is a clinical-stage biotechnology company with a single core product pipeline. PRO-203 is a bispecific CD20xCD3 T-cell engager in-licensed from KeyMed Biosciences and InnoCare Pharma, representing the company's primary therapeutic candidate for treating severe autoimmune diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- PRO-203 PRO-203 is a bispecific CD20xCD3 T-cell engager antibody being developed by Prolium Bioscience for severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The therapeutic candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. It is intended for patients with treatment-refractory severe autoimmune disorders.
- PRO-203 Phase 1/2 Clinical Study in Systemic Sclerosis A multinational Phase 1/2 clinical trial evaluating PRO-203 in patients with systemic sclerosis. The study is being conducted by Prolium Bioscience to assess safety, tolerability, and efficacy of the bispecific CD20xCD3 T-cell engager in this severe autoimmune indication. The trial is part of Prolium's core clinical development program.
Quantifiable outcome
- 59% complete response rate and 82% overall response rate in relapsed/refractory Non-Hodgkin Lymphoma at therapeutic doses
Companies that use Prolium
Customer profileSegments1 record
Ideal customer profiles1 record
Prolium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Prolium partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- KeyMed BiosciencescoreProlium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from KeyMed Biosciences. KeyMed previously showed 59% CR and 82% ORR in NHL Phase 1/2 trials.
- InnoCare PharmacoreProlium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from InnoCare Pharma, in addition to KeyMed Biosciences.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Prolium competitors and assessment
Company assessmentBroad incumbents
- AbbVie: AbbVie is the commercial partner for epcoritamab (CD20xCD3 bispecific) and has a broad immunology franchise including HUMIRA, SKYRIZI, and RINVOQ. As a leader in autoimmune disease therapeutics, it represents a major incumbent competitor and potential strategic acquirer for Prolium's technology.
- Roche: Roche developed glofitamab and mosunetuzumab, both CD20xCD3 bispecific antibodies approved or in late-stage development for lymphoma. As an established leader in the CD20xCD3 space, Roche is a direct competitive incumbent for Prolium's mechanism, though with vastly broader portfolio scale.
Direct peers
- Cabaletta Bio: Cabaletta Bio is a clinical-stage biotechnology company developing CD19 CAR-T cell therapies for autoimmune diseases, including lupus and systemic sclerosis. It is directly comparable to Prolium in pursuing deep B-cell depletion for severe autoimmune indications.
- Genmab: Genmab is a biotechnology company specializing in antibody therapeutics, including the CD20xCD3 bispecific T-cell engager epcoritamab. It is directly comparable to Prolium given its leadership in CD20xCD3 bispecific antibody technology and its application across oncology and emerging autoimmune indications.
- Regeneron Pharmaceuticals: Regeneron is developing odronextamab, a CD20xCD3 bispecific antibody, and has deep antibody engineering capabilities (VelociSuite). It is comparable to Prolium in pursuing CD20xCD3 bispecifics, though at significantly larger scale and with broader pipeline scope.
- Kyverna Therapeutics: Kyverna Therapeutics is developing CD19 CAR-T cell therapies for autoimmune diseases including lupus nephritis and other B-cell-driven conditions. It is directly comparable to Prolium in targeting severe autoimmune diseases via B-cell depletion, though using a cell therapy rather than a bispecific antibody.
Emerging players
- Argenx: Argenx is a biotechnology company developing antibody-based therapies for severe autoimmune diseases, with lead asset efgartigimod (FcRn antagonist) approved for myasthenia gravis. It is comparable to Prolium in focusing on biologics for severe autoimmune indications, though with a different mechanism.
- Caribou Biosciences: Caribou Biosciences is developing allogeneic CAR-T cell therapies for autoimmune diseases and oncology. It is comparable to Prolium in pursuing B-cell-directed therapies for severe autoimmune indications, though using an allogeneic cell therapy platform.
- Cullinan Therapeutics: Cullinan Therapeutics develops T-cell engagers and other oncology and autoimmune therapies, including immune-mediated disease programs. It is comparable to Prolium as an emerging clinical-stage company with TCE-focused pipeline strategy.
Others
- KeyMed Biosciences: KeyMed Biosciences is the originator and licensor of PRO-203 to Prolium. It is comparable as the developer of the underlying CD20xCD3 bispecific antibody technology and remains a strategic partner and potential ecosystem participant for Prolium.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Prolium social profiles
Digital presenceProlium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prolium leadership team
Management profileNumber of profiles
Profiles4 records
Prolium funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prolium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prolium
What does Prolium do?
Prolium Bioscience is developing PRO-203, a bispecific CD20xCD3 T-cell engager antibody in-licensed from KeyMed Biosciences and InnoCare Pharma, for the treatment of severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. The company is currently running a single ascending dose study in healthy volunteers and plans a multinational Phase 1/2 study in systemic sclerosis.
Is Prolium a public or private company?
Prolium is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prolium founded?
Prolium was founded in 2026. It employs 1 to 10 people.
Where is Prolium based?
Prolium is headquartered in New York, United States, in the North America region.
How does Prolium make money?
One revenue line is on record: drug Development and Commercialization.
Who are Prolium's main competitors?
Broad incumbents on record are AbbVie and Roche. Direct peers are Cabaletta Bio, Genmab, Regeneron Pharmaceuticals and Kyverna Therapeutics. Emerging players are Argenx, Caribou Biosciences and Cullinan Therapeutics. KeyMed Biosciences is listed as an others.
Does Prolium have an API?
No public API is recorded for Prolium.
What industry is Prolium in?
Prolium's product category is Biopharmaceuticals / Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 541714 and its SIC code is 2836.